JSON
Borgatti A, Koopmeiners JS, Sarver AL, Winter AL, Stuebner K, Todhunter D, Rizzardi AE, Henriksen JC, Schmechel S, Forster CL, Kim JH, Froelich J, Walz J, Henson MS, Breen M, Lindblad-Toh K, Oh F, Pilbeam K, Modiano JF, Vallera DA
Mol. Cancer Ther. 16 (5) 956-965 [2017-05-00; online 2017-02-13]
Sarcomas differ from carcinomas in their mesenchymal origin. Therapeutic advancements have come slowly, so alternative drugs and models are urgently needed. These studies report a new drug for sarcomas that simultaneously targets both tumor and tumor neovasculature. eBAT is a bispecific angiotoxin consisting of truncated, deimmunized
PubMed 28193671
DOI 10.1158/1535-7163.MCT-16-0637
Crossref 10.1158/1535-7163.MCT-16-0637
pii: 1535-7163.MCT-16-0637
pmc: PMC5418099
mid: NIHMS849663